VE-303 is under clinical development by Vedanta Biosciences and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect VE-303’s likelihood of approval (LoA) and phase transition for Cirrhosis took place on 03 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VE-303 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

VE-303 overview

VE-303 is under development for the treatment of cirrhosis, hepatic encephalopathy, colitis and Clostridium difficile infections. It is administered through oral route and formulated as a capsule. The drug candidate consists of a defined consortia of live bacteria. It acts by modulating pathways of interaction between the human microbiome and the host immune system to treat inflammatory diseases.

Vedanta Biosciences overview

Vedanta Biosciences is a clinical-stage company which focuses on microbiome, which performs critical functions that preserve health including modulating our immune system and providing colonization resistance against infectious pathogens. Vedanta Biosciences is headquartered in Cambridge, Massachusetts, the US.

Quick View VE-303 LOA Data

Report Segments
  • Innovator
Drug Name
  • VE-303
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.